Taneptacogin alfa
Alternative Names: Active Site Inactivated Seven; Active Site Inhibited Seven; ASIS; FFR-FVIIa; FFR-VIIaLatest Information Update: 24 Oct 2021
At a glance
- Originator Novo Nordisk
- Class
- Mechanism of Action Factor VIIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Coronary artery restenosis; Thrombosis; Vascular restenosis
Most Recent Events
- 07 Sep 2004 Discontinued - Phase-II for Adult respiratory distress syndrome (unspecified route)
- 06 Feb 2003 Phase-II clinical trials in Adult respiratory distress syndrome (unspecified route)
- 21 Sep 2000 Discontinued-II for Coronary artery restenosis in Europe (Unknown route)